Results 181 to 190 of about 55,676 (335)

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

, 2016
Eugene Guorong Yang, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Pondy Murugappan Ramanujulu, Wee Joo Chng, J. J. Yen, Brian Dymock   +7 more
openalex   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 [PDF]

, 2020
Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia   +2 more
openalex   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice [PDF]

, 2014
Carlota Recio, Ainhoa Oguiza, Iolanda Lázaro, Beñat Mallavia, Jesús Egido, Carmen Gómez‐Guerrero   +5 more
openalex   +1 more source

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib [PDF]

Justin Arnall, Lindsey Lyle, Donald C. Moore   +2 more
openalex   +1 more source

Data from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Jih‐Hsiang Lee, Kang‐Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng‐Tzu Weng, Yisong Wang, Giuseppe Giaccone   +6 more
openalex   +1 more source

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. [PDF]

Pharmacol Rev, 2020
Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ.   +3 more
europepmc   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source